Thiazolidinediones improve flow-mediated dilation: A meta-analysis of randomized clinical trials

European Journal of Clinical Pharmacology

Volumn 72, Issue 4, 2016, Pages 385-398

  Stojanović, Marko ^a   Prostran, Milica ^a   Radenković, Miroslav ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Endothelial dysfunction; Flow mediated dilation; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONOXINOL 9; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

AGE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; COCHRANE LIBRARY; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED DILATION; GENDER; HUMAN; LIPID ANALYSIS; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WEB OF SCIENCE; ANIMAL; DRUG EFFECTS; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; VASODILATION;

EID: 84962216717     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1999-4     Document Type: Review

References (50)

1. Radenković M (2014) Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications. Sci Pharm 82:709-721
2. Diamant M, Heine RJ (2003) Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63:1373-1405
3. Radenković M, Stojanović M, Potpara T, Prostran M (2013) Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art. Biomed Res Int 2013:252158
4. Stojanović M, Radenković M (2015) Vitamin D versus placebo in improvement of endothelial dysfunction: a meta-analysis of randomized clinical trials. Cardiovasc Ther 33:145-154
5. Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al. (2015) The role of vascular biomarkers for primary and secondary prevention. Atherosclerosis 241:507-532
6. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, et al. (2011) Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 215:180-183
7. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y (2009) Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J 56:691-698
8. Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D, Fonseca V (2006) Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord 4:179-184
9. Hong SJ, Choi SC, Cho JY, Joo HJ, Park JH, Yu CW, et al. (2015) Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. Circ J 79:880-888
10. Rudofsky Jr G, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, et al. (2007) Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity. Horm Metab Res 39:665-671
11. Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA (2011a) Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 95:203-209
12. Lee JW, Hong SJ, Jeong HS, Joo HJ, Park JH, Ahn CM, et al. (2013) Effects of a PPAR-γ (peroxisome proliferator-activated receptor-gamma) activator on flow-mediated brachial artery dilation and circulating level of microRNA-21 in hypertensive type 2 diabetic patients. J Korean Soc Hypertens 19:99-111
13. Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C (2011b) Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin. Diab Vasc Dis Res 8:195-201
14. Walcher T, Walcher D, Hetzel J, Mielke C, Rau M, Rittig K, et al. (2010) Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. Diab Vasc Dis Res 7:178-185
15. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT (2006) Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98:1057-1062
16. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, et al. (2006) Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29:1071-1076
17. Desch S, Sonnabend M, Niebauer J, Sixt S, Sareban M, Eitel I, et al. (2010) Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes. Diabetes Obes Metab 12:825-828
18. Sidhu JS, Cowan D, Kaski JC (2004) Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 94:151-156
19. Chan DT, Watts GF, Irish AB, Dogra GK (2011) Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dial Transplant 26:3543-3549
20. Sixt S, Rastan A, Desch S, Sonnabend M, Schmidt A, Schuler G, et al. (2008) Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease. Eur J Cardiovasc Prev Rehabil 15:473-478
21. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, et al. (2003) The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52:173-180
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100
23. Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.3.0. The Cochrane Collaboration. www.cochranehandbook.org
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12
25. Sahebkar A (2014) Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Vasc Med 19:54-66
26. Lunder M, Janić M, Jug B, Sabovič M (2012) The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med 23:261-266
27. Takagi H, Umemoto T (2014) A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation. Hypertens Res 37:845-851
28. Li S, Wu Y, Yu G, Xia Q, Xu Y (2014) Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials. PLoS One 9:e90217
29. Zhang L, Gong D, Li S, Zhou X (2012) Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 223:78-85
30. Shahin Y, Khan JA, Samuel N, Chetter I (2011) Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 216:7-16
31. Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, et al. (2012) Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 221:536-543
32. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 88:38-50
33. Ashor AW, Lara J, Siervo M, Celis-Morales C, Oggioni C, Jakovljevic DG, et al. (2015) Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials. Sports Med 45:279-296
34. Li SH, Tian HB, Zhao HJ, Chen LH, Cui LQ (2013) The acute effects of grape polyphenols supplementation on endothelial function in adults: meta-analyses of controlled trials. PLoS One 8:e69818
35. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P (2005) Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54:2206-2211
36. Albertini JP, McMorn SO, Chen H, Mather RA, Valensi P (2007) Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 195:e159-e166
37. Perampaladas K, Gori T, Parker JD (2012) Rosiglitazone causes endothelial dysfunction in humans. J Cardiovasc Pharmacol Ther 17:260-265
38. Takase H, Nakazawa A, Yamashita S, Toriyama T, Sato K, Ueda R, et al. (2007) Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 56:559-564
39. Tahara N, Yamagishi S, Mizoguchi M, Tahara A, Imaizumi T (2013) Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res 16:344-351
40. King DE, Player M, Everett CJ (2012) The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes. Prim Care Diabetes 6:157-161
41. Matsumoto T, Noguchi E, Kobayashi T, Kamata K (2007) Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free RadicBiol Med 42:993-1007
42. Hernanz R, Martín Á, Pérez-Girón JV, Palacios R, Briones AM, Miguel M, et al. (2012) Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol 166:1303-1319
43. Lu X, Guo X, Karathanasis SK, Zimmerman KM, Onyia JE, Peterson RG, et al. (2010) Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats. Cardiovasc Diabetol 9:19
44. Kaur T, Goel RK, Balakumar P (2010) Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Arch Pharm Res 33:611-618
45. Khazaei M, Salehi E (2012) Rosiglitazone enhances neovascularization in diabetic rat ischemic hindlimb model. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156:312-317
46. Sigmund CD (2010) Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension 55:437-444
47. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 3:845-851
48. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
49. Woodcock J, Sharfstein JM, Hamburg M (2014) Regulatory action on rosiglitazone by the U.S. Food and drug administration. N Engl J Med 363:1489-1491
50. Wang T, Ning G, Bloomgarden Z (2013) Diabetes and cancer relationships. J Diabetes 5:378-390